Olio and AION Biosystems Partner to Close the Post-Discharge Blind Spot

When patients transition out of skilled nursing facilities, continuous clinical monitoring stops. A new partnership between Olio and AION Biosystems changes that — embedding real-time infection detection into the SNF care workflow for the first time.

INDIANAPOLIS--(BUSINESS WIRE)--Olio, a care coordination platform for post-acute and behavioral health networks, announced a strategic partnership with AION Biosystems, maker of the TempShield™, an FDA-cleared wearable that continuously monitors body temperature, capturing subtle changes that can signal early clinical deterioration to support earlier intervention and improved outcomes. The collaboration integrates TempShield™ with Olio's post-discharge coordination and Safe Return workflows to detect and respond to early signs of infection in patients transitioning from SNFs to home health and hospice care.

Care transitions are high-risk moments. When a patient walks out the door, continuous clinical monitoring stops along with any chance of early intervention. For patients already vulnerable to infection, that gap is dangerous: Nursing home residents are 7x more likely than non-residents to develop severe sepsis, and for every hour of delayed treatment, sepsis mortality increases by 7.6%.

There are more than 15,000 SNFs managing these critical transitions. Undetected infections lead to negative operational consequences, including avoidable readmissions, eroding quality scores, and damaged referral relationships.

"Once a patient leaves the facility, the physiological data disappears," said Ben Forrest, CEO of Olio. "TempShield closes that gap. Paired with Olio, care teams can act on the first sign of trouble, instead of reacting after it becomes an emergency."

Placed on patients at the point of discharge, the device monitors body temperature continuously for up to 90 days, capturing biometric temperature trends that can be associated with emerging infections. TempShield data feeds directly into Olio's Safe Return workflows, enabling care teams to detect a concerning change and intervene before it escalates to a hospital readmission.

In a program with Trilogy Health Services, use of TempShield was associated with a 67% hospital prevention rate among monitored residents, driven by earlier recognition of changes in patient condition and timely clinical intervention. Following TempShield alerts, clinical evaluations identified a range of conditions observed in practice, including respiratory and infectious complications such as UTIs, pneumonia, bronchitis, C. diff, and COPD exacerbations.

"AION TempShield has been indispensable because it seamlessly integrated into our systems and workflows, enabled early detection of illness, and reduces hospitalizations - without creating additional work for nurses - supporting care and value-based outcomes" - Rhonda Dempsey, RN, LNHA, MBA, SVP Chief Nursing Officer of Trilogy Health Services.

"A device is only as good as the system around it," said Samara Barend, CEO of AION Biosystems. "Olio provides exactly the coordination infrastructure that turns our data into action. A patient goes home wearing a TempShield, and if their temperature trends the wrong direction at 2 a.m., there's a care plan in motion by sunrise — not three days later in an ER."

About Olio Olio modernizes care transitions across the entire patient journey. It connects care teams and keeps them engaged while delivering the insights organizations need to improve outcomes and reduce costs. www.olio.health

About AION Biosystems AION Biosystems is the maker of the TempShield™ — an FDA-cleared wearable that continuously monitors body temperature, capturing subtle changes that can signal early clinical deterioration to support earlier intervention and improved outcomes. aionbiosystems.com